A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies
Copyright © 2022. Published by Elsevier Inc..
BACKGROUND: The Janus kinase (JAK)/signal transducers and activators of transcription pathway has been implicated in the pathogenesis and progression of various hematologic malignancies. JAK1-regulated cytokines stimulate proliferation and growth of malignant cells and resistance to certain therapies.
PATIENTS AND METHODS: This phase 1/2 study evaluated 2 oral, novel JAK1 inhibitors (INCB052793 and itacitinib) in advanced hematologic malignancies. Phase 1a assessed dose escalation and expansion of INCB052793 monotherapy. Phase 1b evaluated INCB052793 plus standard therapy in relapsed/refractory multiple myeloma, acute myeloid leukemia (AML), or myelodysplastic syndrome (MDS). Phase 2 evaluated INCB052793 or itacitinib plus azacitidine in DNA methyltransferase inhibitor (DNMTi)-refractory AML or MDS. Primary endpoints included safety and tolerability for phase 1, and objective response rate for phase 2.
RESULTS: Fifty-eight patients were enrolled, all received study treatment and discontinued either treatment or participation in the study. The most common reasons for treatment discontinuation were progressive disease (35.4% and 50.0%) and adverse events (22.9% and 20.0%) for INCB052793 and itacitinib plus azacitidine, respectively. In phase 1, 12 of 39 patients (31%) achieved an objective response; 35 mg once daily was selected as the phase 2 dose. Two patients with DNMTi-refractory disease had an objective response in phase 2. The study was terminated for lack of efficacy.
CONCLUSION: Inhibition of JAK1 with INCB052793 (monotherapy or combination therapy) or itacitinib plus azacitidine did not demonstrate clinically meaningful responses in these patients with hematopoietic malignancies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Clinical lymphoma, myeloma & leukemia - 22(2022), 7 vom: 30. Juli, Seite 523-534 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zeidan, Amer M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.06.2022 Date Revised 18.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clml.2022.01.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337912718 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337912718 | ||
| 003 | DE-627 | ||
| 005 | 20231225235507.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clml.2022.01.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM337912718 | ||
| 035 | |a (NLM)35260349 | ||
| 035 | |a (PII)S2152-2650(22)00016-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zeidan, Amer M |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.06.2022 | ||
| 500 | |a Date Revised 18.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier Inc. | ||
| 520 | |a BACKGROUND: The Janus kinase (JAK)/signal transducers and activators of transcription pathway has been implicated in the pathogenesis and progression of various hematologic malignancies. JAK1-regulated cytokines stimulate proliferation and growth of malignant cells and resistance to certain therapies | ||
| 520 | |a PATIENTS AND METHODS: This phase 1/2 study evaluated 2 oral, novel JAK1 inhibitors (INCB052793 and itacitinib) in advanced hematologic malignancies. Phase 1a assessed dose escalation and expansion of INCB052793 monotherapy. Phase 1b evaluated INCB052793 plus standard therapy in relapsed/refractory multiple myeloma, acute myeloid leukemia (AML), or myelodysplastic syndrome (MDS). Phase 2 evaluated INCB052793 or itacitinib plus azacitidine in DNA methyltransferase inhibitor (DNMTi)-refractory AML or MDS. Primary endpoints included safety and tolerability for phase 1, and objective response rate for phase 2 | ||
| 520 | |a RESULTS: Fifty-eight patients were enrolled, all received study treatment and discontinued either treatment or participation in the study. The most common reasons for treatment discontinuation were progressive disease (35.4% and 50.0%) and adverse events (22.9% and 20.0%) for INCB052793 and itacitinib plus azacitidine, respectively. In phase 1, 12 of 39 patients (31%) achieved an objective response; 35 mg once daily was selected as the phase 2 dose. Two patients with DNMTi-refractory disease had an objective response in phase 2. The study was terminated for lack of efficacy | ||
| 520 | |a CONCLUSION: Inhibition of JAK1 with INCB052793 (monotherapy or combination therapy) or itacitinib plus azacitidine did not demonstrate clinically meaningful responses in these patients with hematopoietic malignancies | ||
| 650 | 4 | |a Clinical Trial, Phase I | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a AML | |
| 650 | 4 | |a JAK/STAT | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 4 | |a Myelodysplastic syndrome | |
| 650 | 4 | |a Relapsed/refractory | |
| 650 | 7 | |a Acetonitriles |2 NLM | |
| 650 | 7 | |a Janus Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Pyrroles |2 NLM | |
| 650 | 7 | |a itacitinib |2 NLM | |
| 650 | 7 | |a 19J3781LPM |2 NLM | |
| 650 | 7 | |a Janus Kinase 1 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 650 | 7 | |a Azacitidine |2 NLM | |
| 650 | 7 | |a M801H13NRU |2 NLM | |
| 700 | 1 | |a Cook, Rachel J |e verfasserin |4 aut | |
| 700 | 1 | |a Bordoni, Rodolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Berenson, James R |e verfasserin |4 aut | |
| 700 | 1 | |a Edenfield, William J |e verfasserin |4 aut | |
| 700 | 1 | |a Mohan, Sanjay |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Gongfu |e verfasserin |4 aut | |
| 700 | 1 | |a Asatiani, Ekaterine |e verfasserin |4 aut | |
| 700 | 1 | |a Srinivas, Nithya |e verfasserin |4 aut | |
| 700 | 1 | |a Savona, Michael R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lymphoma, myeloma & leukemia |d 2010 |g 22(2022), 7 vom: 30. Juli, Seite 523-534 |w (DE-627)NLM195738748 |x 2152-2669 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:7 |g day:30 |g month:07 |g pages:523-534 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clml.2022.01.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 7 |b 30 |c 07 |h 523-534 | ||